Protagonist Therapeutics/$PTGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Ticker
- $PTGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 149
- Headquarters
- Newark, United States
- Website
- www.protagonist-inc.com
PTGX Metrics
BasicAdvanced
$8.1B
25.17
$4.93
1.22
-
Price and volume
Market cap
$8.1B
Beta
1.22
52-week high
$160.81
52-week low
$77.00
Average daily volume
642K
Financial strength
Current ratio
19.852
Quick ratio
19.76
Long term debt to equity
0.006
Total debt to equity
0.011
Profitability
EBITDA (TTM)
324.662
Gross margin (TTM)
99.80%
Net profit margin (TTM)
62.04%
Operating margin (TTM)
58.56%
Effective tax rate (TTM)
2.28%
Revenue per employee (TTM)
$3,700,000
Management effectiveness
Return on assets (TTM)
21.85%
Return on equity (TTM)
39.56%
Valuation
Price to earnings (TTM)
25.171
Price to revenue (TTM)
14.693
Price to book
9.53
Price to tangible book (TTM)
9.53
Price to free cash flow (TTM)
74.264
Free cash flow yield (TTM)
1.35%
Free cash flow per share (TTM)
1.67
Growth
Revenue change (TTM)
163.69%
Earnings per share change (TTM)
584.10%
3-year earnings per share growth (CAGR)
23.70%
10-year earnings per share growth (CAGR)
-9.59%
What the Analysts think about PTGX
Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.
Analyst projections of the future price of Protagonist Therapeutics stock.
Bulls say / Bears say
Rusfertide (MIMRYLO) has progressed from a successful Phase 3 trial to FDA approval: 76.9% of patients responded, versus 32.9% on placebo, and the trial also showed improved fatigue. Approval triggered $275 million in payments, with 14%–29% royalties on future worldwide sales. (Newswire, U.S. Securities and Exchange Commission)
Icotrokinra is approved in the US, EU, Japan and China, and is being tested in Phase 3 for further immune diseases, including psoriatic arthritis, ulcerative colitis and Crohn’s disease. Those uses could add to PTGX’s 6%–10% royalties and up to $580 million in potential milestones from J&J. (U.S. Securities and Exchange Commission)
PTGX had $834.6 million in cash, equivalents and marketable securities at 30 September, giving it resources to advance its own pipeline. Its oral IL-17 candidate PN-881 showed Phase 1 drug levels above targeted thresholds, with a Phase 2b psoriasis study planned for early 2027. (U.S. Securities and Exchange Commission)
Third-quarter net income was $220 million, but $266.6 million of the quarter’s $274.4 million collaboration revenue came from recognition of Takeda opt-out and approval payments. That makes the reported profit a poor guide to recurring earnings from product sales. (U.S. Securities and Exchange Commission)
PTGX does not control the commercial effort behind either approved drug: Takeda has exclusive worldwide rights to MIMRYLO, while J&J handles ICOTYDE’s development and sales. Future royalties and milestones therefore depend on partners’ launch execution and the medicines’ uptake. (U.S. Securities and Exchange Commission)
In a Phase 3 psoriasis comparison, icotrokinra was non-inferior to ustekinumab but did not show statistical superiority. That may make it harder to stand out against established treatments and win market share. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.
PTGX Financial Performance
Revenues and expenses
PTGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PTGX News
AllArticlesVideos

Protagonist Therapeutics Announces $300 Million Share Repurchase Program
Accesswire2 months ago

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
Accesswire3 months ago

Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
MarketBeat3 months ago
Funds containing PTGX
Fund name | Fund size | $PTGX weighting |
|---|---|---|
iShares Ageing Population£AGES | $887M | 0.60% |
iShares Ageing Population$AGED | $887M | 0.60% |
iShares Ageing Population€AGED | $887M | 0.60% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.55% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.55% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.